Bialik, R. J., Ravindran, A. V., Bakish, D., et al (1995) A comparison of placebo responders and nonresponders in subgroups of depressive disorder. Journal of Psychiatry and Neuroscience, 20, 265–270.
Brownell, K. & Stunkard, A. (1982) The double blind in danger: untoward consequences of informed consent. American Journal of Psychiatry, 139, 1487–1489.
Bystritsky, A. & Waikar, S. V. (1994) Inert placebo versus active medication. Patient blindability in clinical pharmacological trials. Journal of Nervous and Mental Disease, 182, 485–487.
Chalmers, T. C., Smith, H., Blackburn, B., et al (1981) A method for assessing the quality of a randomized control trial. Controlled Clinical Trials, 2, 31–49.
Engelhardt, D. M., Margolis, R. A., Rudorfer, L., et al (1969) Physician bias and the double-blind. Archives of General Psychiatry, 20, 315–320.
Fairchild, C. J., Rush, A. J., Vasavada, N., et al (1986) Which depressions respond to placebo?
Psychiatry Research, 18, 217–226.
Greenberg, R. P., Bornstein, R. F., Greenberg, M. D., et al (1992) A meta-analysis of antidepressant outcome under ‘blinder$’ conditions. Journal of Consulting and Clinical Psychology, 60, 664–669.
Greenberg, R. P., Bornstein, R. F., Zborowski, M. J., et al (1994) A meta-analysis of fluoxetine outcome in the treatment of depression. Journal of Nervous and Mental Disease, 182, 547–551.
Healy, D. (1998) Meta-analysis of trials comparing antidepressants with active placebos (commentary). British Journal of Psychiatry, 172, 232–234.
Henker, B., Whalen, C. K. & Collins, B. E. (1979) Double-blind and triple-blind assessments of medication and placebo responses in hyperactive children. Journal of Abnormal Child Psychology, 7, 1–13.
Howard, J., Whittemore, A. S., Hoover, J. J., et al (1982) How blind was the patient blind in AMIS?
Clinical Pharmacology and Therapeutics, 32, 543–553.
Hughes, J. & Krahn, D. (1985) Blindness and the validity of the double-blind procedure. Journal of Clinical Psychopharmacology, 5, 138–142.
Leber, P. D. (1989) Hazards of inference: the active control investigation. Epilepsia, 30, 57–63; discussion 64–68.
Margraf, J., Ehlers, A., Roth, W. T., et al (1991) How ‘blind$’ are double-blind studies?
Journal of Consulting and Clinical Psychology, 59, 184–187.
Moncrieff, J., Wessely, S. & Hardy, R. (1998) Meta-analysis of trials comparing antidepressants with active placebos. British Journal of Psychiatry, 172, 227–231.
Muller, H. & Moller, H. J. (1998) Methodological problems in the estimation of the onset of the antidepressant effect. Journal of Affective Disorders, 48, 15–23.
Oxtoby, A., Jones, A. & Robinson, M. (1989) Is your ‘double-blind$’ design truly double-blind?
British Journal of Psychiatry, 155, 700–701.
Rabkin, J., Markowitz, J., Stewart, J., et al (1986) How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Research, 19, 75–86.
Snyder, S. & Yamamura, H. (1977) Antidepressants and the muscarinic acetylcholine receptor. Archives of General Psychiatry, 2, 236–239.
Streiner, D. L. (1995) Learning how to differ: agreement and reliability statistics in psychiatry. Canadian Journal of Psychiatry, 40, 60–66.
Thomson, R. (1982) Side effects and placebo amplification. British Journal of Psychiatry, 140, 64–68.
White, K., Kando, J., Park, T., et al (1992) Side effects and the ‘blindability$’ of clinical drug trials. American Journal of Psychiatry, 149, 1730–1731.